- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on May 25, 2013
b3c newswire
>6th Monolith Summer School & Symposium to be held on May 30th - June 4th, 2014, Slovenia
>Biotage and Peptide Synthesis
>Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
>6th Monolith Summer School & Symposium to be held on May 30th - June 4th, 2014, Slovenia
>Biotage and Peptide Synthesis
>Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
BioSpace
>Johnson & Johnson: We're Creaming Medivation, Inc., Boehringer Ingelheim Corporation, Bristol-Myers Squibb Company and Pfizer Inc.
>Bird Flu Virus is Capable of Human Spread, University of Hong Kong Study
>Cinnamon May Prevent Alzheimer's Disease, University of California, Santa Barbara Study
>Novartis AG Admits Employees Participated in Independent Trials
>People With Higher IQ Ignore Distractions Better, University of Rochester Study
>Johnson & Johnson: We're Creaming Medivation, Inc., Boehringer Ingelheim Corporation, Bristol-Myers Squibb Company and Pfizer Inc.
>Bird Flu Virus is Capable of Human Spread, University of Hong Kong Study
>Cinnamon May Prevent Alzheimer's Disease, University of California, Santa Barbara Study
>Novartis AG Admits Employees Participated in Independent Trials
>People With Higher IQ Ignore Distractions Better, University of Rochester Study
BioSpace - Breaking News
>Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG
>BioInvent Recruits as New CEO
>Marc Le Bozec Joins Cytoo as CEO
>Macrocyclics to Collaborate With Roche on Molecular Innovation for Nuclear Medicine
>How Much?! AbbVie Raises Niaspan Price Despite Study Failures
>Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG
>BioInvent Recruits as New CEO
>Marc Le Bozec Joins Cytoo as CEO
>Macrocyclics to Collaborate With Roche on Molecular Innovation for Nuclear Medicine
>How Much?! AbbVie Raises Niaspan Price Despite Study Failures
Biotech News - Business Wire
>Model N to Present at the Raymond James Internet & Software Crossover Conference
>BioNJ Announces Keynote Speakers for BioP 4th Annual International BioPartnering Conference
>Digital Pathology Systems Sector Discussed in Comprehensive Global Industry Analysts Study Published at MarketPublishers.com
>Company Profile for AIBioTech
>La tecnologia di denervazione renale EnligHTN è in grado di ridurre la pressione arteriosa in maniera sicura, rapida e sostenuta, secondo i dati relativi al periodo di un anno derivati dallo studio di St. Jude Medical.
>Model N to Present at the Raymond James Internet & Software Crossover Conference
>BioNJ Announces Keynote Speakers for BioP 4th Annual International BioPartnering Conference
>Digital Pathology Systems Sector Discussed in Comprehensive Global Industry Analysts Study Published at MarketPublishers.com
>Company Profile for AIBioTech
>La tecnologia di denervazione renale EnligHTN è in grado di ridurre la pressione arteriosa in maniera sicura, rapida e sostenuta, secondo i dati relativi al periodo di un anno derivati dallo studio di St. Jude Medical.
Biotech News - PR Newswire
>Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas
>joimax® Presents EndoLIF® as a World Premiere at the Annual Meeting of DGNC
>InspireMD To Participate In Benchmark Investor Conference On May 30th
>SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
>Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
>Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas
>joimax® Presents EndoLIF® as a World Premiere at the Annual Meeting of DGNC
>InspireMD To Participate In Benchmark Investor Conference On May 30th
>SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE
>Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
Burrill Report
>Elan Strikes More Deals, Rejects Sweetened Royalty Pharma Bid
>GSK and BARDA Collaborate to Develop New Antibiotics
>Pfizer Drug Fails Three Late-stage Trials
>Industry Advocates Ally to Lobby for Tax Reforms
>Stem Cell Policy Group Folds Tent
>Elan Strikes More Deals, Rejects Sweetened Royalty Pharma Bid
>GSK and BARDA Collaborate to Develop New Antibiotics
>Pfizer Drug Fails Three Late-stage Trials
>Industry Advocates Ally to Lobby for Tax Reforms
>Stem Cell Policy Group Folds Tent
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
Clinical Trials - Business Wire
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
Clinical Trials - PR Newswire
>First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams
>Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
>Clinical trial tests targeting prostate cancer treatment
>First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
>Intensified, Liposomal Anthracycline-Based Chemo Regimen for Children with Leukemia May Offer High Survival Rates Without Added Heart Toxicity
>First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams
>Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
>Clinical trial tests targeting prostate cancer treatment
>First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
>Intensified, Liposomal Anthracycline-Based Chemo Regimen for Children with Leukemia May Offer High Survival Rates Without Added Heart Toxicity
CNN Top Stories
>Explosive device sent to Arpaio
>Judge: Sheriff Arpaio racially profiles
>Principals: School day started out good
>London police make terror arrest
>Healing the horses hurt in tornado
>Explosive device sent to Arpaio
>Judge: Sheriff Arpaio racially profiles
>Principals: School day started out good
>London police make terror arrest
>Healing the horses hurt in tornado
Contract Pharma
>Sangamo BioSciences, CIRM In Strategic Pact
>Macrocyclics, Roche in Nuclear Medicine Pact
>Halozyme Names CFO
>Forest Labs Leader To Step Down
>Chembio Diagnostics Adds COO Position
>Sangamo BioSciences, CIRM In Strategic Pact
>Macrocyclics, Roche in Nuclear Medicine Pact
>Halozyme Names CFO
>Forest Labs Leader To Step Down
>Chembio Diagnostics Adds COO Position
FDA Drugs- What's New
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
FDA News - Business Wire
>La tecnologia di denervazione renale EnligHTN è in grado di ridurre la pressione arteriosa in maniera sicura, rapida e sostenuta, secondo i dati relativi al periodo di un anno derivati dallo studio di St. Jude Medical.
>Celgene anuncia que FDA dos EUA concede revisão prioritária para sNDA do ABRAXANE® em câncer de pâncreas avançado
>Celgene????????????ABRAXANE®?????????FDA??????
>Celgene teilt mit, dass die US-amerikanische Arzneimittelbehörde FDA ein beschleunigtes Zulassungsverfahren für die beantragte Indikationserweiterung für ABRAXANE® bei fortgeschrittenem Bauchspeicheldrüsenkrebs gewährt hat
>Einjahresdaten aus Studie von St. Jude Medical zeigen sichere, schnelle und nachhaltige Blutdrucksenkung mit EnligHTN-Technologie für renale Denervierung
>La tecnologia di denervazione renale EnligHTN è in grado di ridurre la pressione arteriosa in maniera sicura, rapida e sostenuta, secondo i dati relativi al periodo di un anno derivati dallo studio di St. Jude Medical.
>Celgene anuncia que FDA dos EUA concede revisão prioritária para sNDA do ABRAXANE® em câncer de pâncreas avançado
>Celgene????????????ABRAXANE®?????????FDA??????
>Celgene teilt mit, dass die US-amerikanische Arzneimittelbehörde FDA ein beschleunigtes Zulassungsverfahren für die beantragte Indikationserweiterung für ABRAXANE® bei fortgeschrittenem Bauchspeicheldrüsenkrebs gewährt hat
>Einjahresdaten aus Studie von St. Jude Medical zeigen sichere, schnelle und nachhaltige Blutdrucksenkung mit EnligHTN-Technologie für renale Denervierung
FDA Press Releases
>FDA alerts health care providers of adverse reactions associated with steroid injections from Main Street Family Pharmacy in Tennessee
>FDA allows marketing of first A1c test labeled for diagnosing diabetes
>FDA expands alert to health care providers about lack of sterility assurance of all sterile drug products from NuVision Pharmacy
>FDA seeks preliminary injunction against New York fish manufacturer
>FDA approves Simponi to treat ulcerative colitis
>FDA alerts health care providers of adverse reactions associated with steroid injections from Main Street Family Pharmacy in Tennessee
>FDA allows marketing of first A1c test labeled for diagnosing diabetes
>FDA expands alert to health care providers about lack of sterility assurance of all sterile drug products from NuVision Pharmacy
>FDA seeks preliminary injunction against New York fish manufacturer
>FDA approves Simponi to treat ulcerative colitis
FDA Vaccines, Blood and Biologics - What's New
>Kcentra (Prothrombin Complex Concentrate, Human)Approval Letter and Product Labeling, Posted: 4/30/2013
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Kcentra (Prothrombin Complex Concentrate, Human)Approval Letter and Product Labeling, Posted: 4/30/2013
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
FierceBiotech
>Merck Serono CEO stakes out Boston biotech startups
>Pfizer denies knowledge of acquired companies' failures in East German drug trials
>We're taking Memorial Day off
>Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma
>Aveo shares shellacked after Astellas drops EU game plan on kidney cancer
>Merck Serono CEO stakes out Boston biotech startups
>Pfizer denies knowledge of acquired companies' failures in East German drug trials
>We're taking Memorial Day off
>Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma
>Aveo shares shellacked after Astellas drops EU game plan on kidney cancer
FierceBiotech IT
>PatientsLikeMe opens up for patient-reported outcomes
>IMS continues cloud deal blitz with Vantage 360 buy
>Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
>Chinese drug giant tackles drug counterfeiting with mobile service
>InSilico Genomics grabs $1.5M for fledgling bioinformatics biz
>PatientsLikeMe opens up for patient-reported outcomes
>IMS continues cloud deal blitz with Vantage 360 buy
>Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
>Chinese drug giant tackles drug counterfeiting with mobile service
>InSilico Genomics grabs $1.5M for fledgling bioinformatics biz
FierceBiotech Research
>Lundbeck depression drug improves attention, memory in animal model
>New agent halts progression of childhood bone cancer in preclinical study
>Cambridge scientists find molecular catalyst behind Alzheimer's
>Researchers pinpoint protein involved in cancer cell death
>Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease
>Lundbeck depression drug improves attention, memory in animal model
>New agent halts progression of childhood bone cancer in preclinical study
>Cambridge scientists find molecular catalyst behind Alzheimer's
>Researchers pinpoint protein involved in cancer cell death
>Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease
FiercePharma
>AbbVie takes some heat for raising price of Niaspan after studies panned it
>FDA responds to one small piece of Avandia criticism
>Novartis apologizes over Diovan study as probe shows employee involvement in trials
>Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board
>J&J plans 25 lines extensions in next four years
>AbbVie takes some heat for raising price of Niaspan after studies panned it
>FDA responds to one small piece of Avandia criticism
>Novartis apologizes over Diovan study as probe shows employee involvement in trials
>Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board
>J&J plans 25 lines extensions in next four years
FiercePharma Manufacturing
>J&J consumer healthcare faces more issues, this time in Brazil
>Wockhardt acknowledges FDA ban, says it could cost $100M
>Glaxo packs up a tablet packaging line in Australia
>FDA cites Boehringer Ingelheim plant in Germany
>Ranbaxy makes manufacturing strides, consent decree dictates how much
>J&J consumer healthcare faces more issues, this time in Brazil
>Wockhardt acknowledges FDA ban, says it could cost $100M
>Glaxo packs up a tablet packaging line in Australia
>FDA cites Boehringer Ingelheim plant in Germany
>Ranbaxy makes manufacturing strides, consent decree dictates how much
FierceVaccines
>Pfizer lays out MRSA vaccine battle plan
>Sanofi edges closer to universal flu vaccine
>Analyst tips cancer immunotherapies, like GSK's, for explosive growth
>Inertia at Pakistan's NIH threatening vaccine programs
>Pfizer points to pandemic potential of Prevnar 13
>Pfizer lays out MRSA vaccine battle plan
>Sanofi edges closer to universal flu vaccine
>Analyst tips cancer immunotherapies, like GSK's, for explosive growth
>Inertia at Pakistan's NIH threatening vaccine programs
>Pfizer points to pandemic potential of Prevnar 13
Health News - BizJournals.com
>Covered California to pay $12M for ad agency and PR over two years
>Merck loses round in Parkinson's fight
>States settle with Cigna over long-term disability insurance
>Court upholds retroactive Medi-Cal cuts
>An HIV vaccine? OHSU says it's close
>Covered California to pay $12M for ad agency and PR over two years
>Merck loses round in Parkinson's fight
>States settle with Cigna over long-term disability insurance
>Court upholds retroactive Medi-Cal cuts
>An HIV vaccine? OHSU says it's close
Health News - CNBC
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
Inside Industry - Gen
>HHS, GSK Hunt for Drugs to Fight Antibiotic Resistance, Bioterrorism
>FDA cGMP Complaints Draw Boehringer Ingelheim Promise of Action
>Empire Genomics Nabs Prostate Cancer Biomarker from Cornell
>Phase III Success for Boehringer Ingelheim Asthma Drug
>HHS, GSK Hunt for Drugs to Fight Antibiotic Resistance, Bioterrorism
>HHS, GSK Hunt for Drugs to Fight Antibiotic Resistance, Bioterrorism
>FDA cGMP Complaints Draw Boehringer Ingelheim Promise of Action
>Empire Genomics Nabs Prostate Cancer Biomarker from Cornell
>Phase III Success for Boehringer Ingelheim Asthma Drug
>HHS, GSK Hunt for Drugs to Fight Antibiotic Resistance, Bioterrorism
Marketwire - Pharma and Biotech
>Call for Nominations: ASC X12 Chair/Vice Chair 2013-2015 Term
>Functional Technologies Receives Extension of Creditor Protection Period
>Annonces en marge de l'assembl?annuelle de Theratechnologies
>Announcements in Conjunction With Theratechnologies Annual Meeting
>Makers of CALPOL(R) Launch a Unique App for the iPhone, Providing Mums With a Helping Hand Whilst Getting Their Little One Back to Normal
>Call for Nominations: ASC X12 Chair/Vice Chair 2013-2015 Term
>Functional Technologies Receives Extension of Creditor Protection Period
>Annonces en marge de l'assembl?annuelle de Theratechnologies
>Announcements in Conjunction With Theratechnologies Annual Meeting
>Makers of CALPOL(R) Launch a Unique App for the iPhone, Providing Mums With a Helping Hand Whilst Getting Their Little One Back to Normal
MassBio News
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
Medical Pharma - PR Newswire
>Brown & Toland Physicians named an "Elite" Medical Group for the Seventh Consecutive Year
>Actavis, Inc. to Present at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference 2013
>Haemonetics to Present at The Jefferies 2013 Global Healthcare Conference
>Bausch + Lomb Announces Settlement with the U.S. Department of Justice to Resolve and Conclude ISTA Pharmaceuticals Investigation
>Dr. Hashim of Beverly Hills, FL has been named a Patients' Choice Award Winner for 2012
>Brown & Toland Physicians named an "Elite" Medical Group for the Seventh Consecutive Year
>Actavis, Inc. to Present at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference 2013
>Haemonetics to Present at The Jefferies 2013 Global Healthcare Conference
>Bausch + Lomb Announces Settlement with the U.S. Department of Justice to Resolve and Conclude ISTA Pharmaceuticals Investigation
>Dr. Hashim of Beverly Hills, FL has been named a Patients' Choice Award Winner for 2012
National Center for Biotechnology Information
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
Nature Biotechnology
>Third oral MS drug wins FDA nod
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Third oral MS drug wins FDA nod
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
New York Times- Biotechnology
>Taking a Chance on a Reverse Merger
>Biotech Firms, Billions at Risk, Lobby States to Limit GenericsThe industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.
>Building a $325,000 Burger
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Taking a Chance on a Reverse Merger
>Biotech Firms, Billions at Risk, Lobby States to Limit GenericsThe industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.
>Building a $325,000 Burger
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
New York Times- Pharmaceuticals
>Ista to Pay $33 Million for Illegal Drug Promotion
>Abscesses Reported After Steroid Injections
>Cervical Cancer Vaccine
>Senate Committee Approves Bill on Compounding
>Unexcited? There May Be a Pill for That.
>Ista to Pay $33 Million for Illegal Drug Promotion
>Abscesses Reported After Steroid Injections
>Cervical Cancer Vaccine
>Senate Committee Approves Bill on Compounding
>Unexcited? There May Be a Pill for That.
OnBioVC
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
Outsourcing-Pharma
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
Pharma News - Business Wire
>California Pharmacists Association Denounces 9th Circuit for Refusing to Review Medi-Cal Cuts Case
>Research and Markets: Global Lung Cancer Pipeline Capsule - 2013 Report Helps Executives Track Competitor Pipeline Molecules
>BioNJ Announces Keynote Speakers for BioP 4th Annual International BioPartnering Conference
>World Ion Channel Modulating Drugs Market Canvassed in Topical Global Industry Analysts Study Published at MarketPublishers.com
>Research and Markets: PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
>California Pharmacists Association Denounces 9th Circuit for Refusing to Review Medi-Cal Cuts Case
>Research and Markets: Global Lung Cancer Pipeline Capsule - 2013 Report Helps Executives Track Competitor Pipeline Molecules
>BioNJ Announces Keynote Speakers for BioP 4th Annual International BioPartnering Conference
>World Ion Channel Modulating Drugs Market Canvassed in Topical Global Industry Analysts Study Published at MarketPublishers.com
>Research and Markets: PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
Pharma News - PharmiWeb
>California Pharmacists Association Denounces 9th Circuit for Refusing to Review Medi-Cal Cuts Case
>BioNJ Announces Keynote Speakers for BioP 4th Annual International BioPartnering Conference
>Company Profile for AIBioTech
>Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference
>Derma Sciences Appoints Medical Device Veteran Amy S. Paul to Its Board of Directors
>California Pharmacists Association Denounces 9th Circuit for Refusing to Review Medi-Cal Cuts Case
>BioNJ Announces Keynote Speakers for BioP 4th Annual International BioPartnering Conference
>Company Profile for AIBioTech
>Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference
>Derma Sciences Appoints Medical Device Veteran Amy S. Paul to Its Board of Directors
Pharma News - PR Newswire
>Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® Distribution
>Avella Founder and CEO John Musil Selected as Ernst & Young Entrepreneur Of The Year® 2013 Finalist
>Volcano stellt bei Präsentationsveranstaltung zu jüngsten klinischen Studien auf der EuroPCR 2013 vorläufige Ergebnisse der ADVISE-II-Studie vor und kündigt Aufnahme in SYNTAX2-Test an
>Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference
>Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
>Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® Distribution
>Avella Founder and CEO John Musil Selected as Ernst & Young Entrepreneur Of The Year® 2013 Finalist
>Volcano stellt bei Präsentationsveranstaltung zu jüngsten klinischen Studien auf der EuroPCR 2013 vorläufige Ergebnisse der ADVISE-II-Studie vor und kündigt Aufnahme in SYNTAX2-Test an
>Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference
>Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
PR Leap - Biotech
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
PRWeb - Biotechnology
>Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding...
>Dr. Ingrid Warmuth Skin Care Center Announces An Open House At Their...
>See What's in Earth's Future ? and Out in Space Now ? at SPIE Optics...
>California Biomedical Industry Leaders Urge Congress to Take Action on...
>Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill,...
>Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding...
>Dr. Ingrid Warmuth Skin Care Center Announces An Open House At Their...
>See What's in Earth's Future ? and Out in Space Now ? at SPIE Optics...
>California Biomedical Industry Leaders Urge Congress to Take Action on...
>Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill,...
PRWeb - Pharmaceuticals
>DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for...
>MOCON Announces Quarterly Dividend
>Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on...
>hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help...
>hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces...
>DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Request for...
>MOCON Announces Quarterly Dividend
>Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on...
>hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help...
>hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces...
Scientific American
>Net Loss: How We Continually Forget What the Oceans Really Used to Be Like [Excerpt]
>Is Global Warming Cooler than Expected?
>Girls Who Are Sexually Abused More Likely to Start Using Substances before Age 10
>3-D Printed Windpipe Gives Infant Breath of Life
>Studies Cast Doubt on Cancer Drug as Alzheimer's Treatment
>Net Loss: How We Continually Forget What the Oceans Really Used to Be Like [Excerpt]
>Is Global Warming Cooler than Expected?
>Girls Who Are Sexually Abused More Likely to Start Using Substances before Age 10
>3-D Printed Windpipe Gives Infant Breath of Life
>Studies Cast Doubt on Cancer Drug as Alzheimer's Treatment
Sports - ESPN Basketball
>DePaul grants Kirk permission to seek transfer
>Green Bay coach to keep job after investigation
>Coach K calls Team USA 'ultimate honor'
>Oladipo, Zeller can have a Wade effect
>Krzyzewski to return as coach of Team USA
>DePaul grants Kirk permission to seek transfer
>Green Bay coach to keep job after investigation
>Coach K calls Team USA 'ultimate honor'
>Oladipo, Zeller can have a Wade effect
>Krzyzewski to return as coach of Team USA
Sports News - ESPN
>SEC hires Vincent as associate commissioner
>Notre Dame paid Weis more than Kelly in 2011
>Elon joining Colonial in latest expansion move
>Sims won't return to Houston for senior season
>Host Finebaum joining SEC Network, ESPN
>SEC hires Vincent as associate commissioner
>Notre Dame paid Weis more than Kelly in 2011
>Elon joining Colonial in latest expansion move
>Sims won't return to Houston for senior season
>Host Finebaum joining SEC Network, ESPN
Xconomy Life Sciences
>Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
>NanoString Technologies Maneuvers In Line for $86M IPO
>Accelerate LI's Lofty Goal: Create the Next U.S. Innovation Cluster
>Zillions of Biotech Conferences Want You. Which Should You Attend?
>XBiotech Takes Aim at Inflammation That Weakens Cancer Patients
>Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
>NanoString Technologies Maneuvers In Line for $86M IPO
>Accelerate LI's Lofty Goal: Create the Next U.S. Innovation Cluster
>Zillions of Biotech Conferences Want You. Which Should You Attend?
>XBiotech Takes Aim at Inflammation That Weakens Cancer Patients
Yahoo Biotech News
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)